|
Orthologous residues
|
|
JunD (human): S100‑p, JunD (mouse): S100‑p, JunD (rat): S100‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
293 (epithelial)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
ERK2 (human)
|
pharmacological inhibitor of upstream enzyme, transfection of constitutively active enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
anisomycin
|
|
|
|
increase
|
|
|
U0126
|
anisomycin
|
|
|
inhibit treatment-induced increase
|
|
|
EGF
|
|
|
|
increase
|
|
|
U0126
|
EGF
|
|
|
inhibit treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (process):
transcription, altered
|